Expression of the leucocyte integrins (CD11a, b, c/CD18) and of CD35 (CR1) on leucocytes from the peripheral blood of patients with rheumatoid arthritis (RA) (n=14) and control subjects (n=12) was measured by flow cytometry using a rapid fixation and leucocyte preparation procedure. The mean (SE) percentages of lymphocytes expressing CD11a (RA 93-4 (1.7)%; controls 97*2 (1.8)%) and CD18 (RA 91-3 (2.3)%; controls 97-0 (2-6)%) were lower and the percentage of monocytes expressing CD11b (RA 86-9 (11-4)%; controls 78-4 (11.9)%) and CR1 (RA 62-6 (15-5)%; controls 36*6 (17.6)%) were higher in patients with RA than in controls. In addition, the mean fluorescence intensity of CD18 (RA 22*1 (2.3); controls 30 7 (2.5)) on lymphocytes was decreased and that of CD11b (RA 4.5 (0.8); controls 2-9 (0.9)) and CR1 (RA 2-4 (0.4); controls 1.5 (0.5)) on monocytes was increased in patients with RA compared with controls. The functional importance (if any) of the altered expression of the antigens on lymphocytes is not yet known. Altered expression on monocytes is consistent with activation within the circulation.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by infiltration of mononuclear cells into the synovium and the accumulation of leucocytes (predominantly polymorphs) in the synovial fluid of the affected joints. A crucial early event in all inflammatory responses is the localised increase in the adhesion of leucocytes to endothelial cells' and several molecules essential to this interaction have been identified.2 3 On leucocytes, the best known adhesion molecules belong to the glycoprotein complex CDll/CD18 (Leu-CAM or the leucocyte integrins). 4 
LEUCOCYTE PREPARATION, LABELLING, AND ANALYSIS
Leucocytes were prepared for labelling using a procedure developed originally for morphological analysis.21 Briefly, blood (0 5 ml) taken from the antecubital vein was mixed immediately with 0-5 ml of prewarmed (37°C) phosphate buffered saline or Hanks's balanced salt solution with 0-01 mol/I HEPES (pH 7 3) (HHBSS) containing 0 4% formaldehyde and stored for 4 min at 37°C. A 20 ml portion of 0-155 mol/l ammonium chloride buffered with 0-01 mol/l TRIS chloride or 0-01 mol/l HEPES (pH 7 3) was added, and when the erythrocytes had lysed (2-4 minutes at 37°C or 8-12 minutes at 20°C), the leucocytes were collected by centrifuging for 5 minutes at 200 g, washed twice by centrifuging for 10 minutes at 200 g in phosphate buffered saline or Hanks's balanced salt solution (first 20 ml, then 10 ml at 0°C), resuspended in 0 5 ml of phosphate buffered saline and stored at 0°C. Cell samples (25 i1) were labelled within two hours. Incubations were performed in a microtitre plate at 0°C using 30 minute periods and the cells were washed after each incubation with 100 1t of medium. RPMI containing 5% fetal calf serum was used as the medium throughout. Control cells were prepared which were either incubated with mouse monoclonal antibody alone or with a subclass matched irrelevant monoclonal antibody (PDS1 or BDS4). Fluorescein conjugated rabbit antimouse Fc F(ab)2 diluted 1:50 was used as the second layer. Labelled cells were resuspended in 25 ,u of RPMI containing 5% fetal calfserum, transferred to round bottomed polystyrene tubes containing 1% paraformaldehyde, left for two hours in the dark at 4°C and analysed by flow cytometry using a FACscan (Becton Dickinson, Mountain View, CA, USA) equipped with Consort 30 software (Hewlett Packard). Polymorphs, monocytes, and lymphocytes were separated on the basis of their forward and side scatter; their identity and purity were established by staining with monoclonal antibodies which identify leucocytes (W6/32 and 2D1), and leucocyte subpopulations (29, TG1, UCHM1 and UCHT1). Fluorescence data were collected on a four decade logarithmic scale. Markers were set on the control antibody, which was PDS1 for monocytes and lymphocytes and UCHT1 for polymorphs because ofthe unusually high non-specific binding of PDS1 by polymorphs. There was generally less than 5% nonspecific staining. The percentage of fluorescent cells was calculated by subtracting the negative control values from the total in each instance. The mean fluorescence intensity ratio was calculated by dividing the mean fluorescence intensity ratio of a leucocyte population labelled with a given monoclonal antibody by the mean fluorescence intensity ratio of the same population labelled with the negative control antibody.
STATISTICAL ANALYSES
ANOVA and the Mann Whitney rank sum test for unpaired data were used to compare data from patients with RA and controls; the two procedures gave essentially similar results. All calculations, correlations, and multiple regression analyses were performed using the 'number cruncher' statistical package on a personal computer; statistical significance was accepted when p<OO5.
Results
The intersubject variation in the proportion of cells expressing a particular surface marker varied greatly among the different markers and leucocyte types. However, figs 1-3 show that the ranges for any given marker and cell type were largely similar for patients with RA and controls, with the exception that the medians for the percentage of lymphocytes expressing CD1 la and CD18 were smaller and those for the percentage of monocytes expressing CD 1 b and CR1 were higher in patients with RA than in controls (figs 1 and 2) .
Similarly, the intersubject variation in the values found for the mean fluorescence intensity ratio of a particular surface marker differed greatly among the various markers and leucocyte types. Figures 4-6 show that, again, the ranges for any given marker and cell type were largely similar for patients with RA and controls. However, the median value of the mean fluorescence intensity ratio for CD18 on lymphocytes was decreased and that for CD llb and CR1 on monocytes were increased in patients with RA compared with controls (figs 4 and 5).
Evidence suggesting that a given a chain might be expressed at similar relative levels on different leucocyte types within patients, was found only for CD1 la on lymphocytes and polymorphs in control subjects and for CD1 lb and CDlIc on monocytes and polymorphs in controls and patients with RA (table 2) . Conversely, evidence suggesting that, within subjects, the different a chains might be expressed at similar relative levels on given leucocyte types, was found only for CDl la and CDl lb on control monocytes, RA lymphocytes, and RA monocytes, and for CD1lb and CD1lc on control and RA monocytes (table 3) . When neutrophils are activated in vitro the surface expression of CR1 and CR3 (CDllb/ CD18) increases in parallel.30 Possible correlations between the mean fluorescence intensity ratio of CR1 and the mean fluorescence intensity ratios of the components of the CDII/CD18 complex were therefore analysed. The 
Discussion
The rapid leucocyte fixation and preparation procedure that was used in these studies was designed specifically to prevent in vitro changes in the surface expression of the leucocyte intergrins. Brief fixation with formaldehyde is known to inhibit the changes in neutrophil shape which accompany activation2' and to preserve the expression of leucocyte surface markers such as CD3, CD4, CD8, and major histocompatibility complex class II (Hamblin et al, unpublished data). Thus, except for any possible changes due to the process of venepuncture itself, we believe that our findings represent the true state of these molecules on the surface of leucocytes from the circulating pool. Our results show considerable intersubject variation in the expression of CR1 and the components of the CDl1/CD18 complex, but are nevertheless broadly consistent with previous findings for normal subjects.4 5 1 31 32 CDIla/ CD18 was expressed on all lymphocytes, monocytes, and polymorphs (figs 1-3), but the level of expression varied from subject to subject (figs 4-6). The percentages of cells expressing CD1 lb and CD1 ic varied greatly and the median values were always lower than those for CDlla (figs 1-3). These results are consistent with CD llb and CDlIc being weakly expressed on leucocytes.
As yet, the mechanisms which regulate the expression of integrins on leucocytes and which presumably contribute to the substantial intersubject variations in expression are only partly understood. To the best of our knowledge, the correlations noted in tables 2-4 have not previously been reported elsewhere and the biological phenomena responsible for these must be largely a matter for speculation. The fact that similar relative amounts of CD1lb and CD1lc were expressed on monocytes and polymorphs from the same subject, irrespective of whether they were patients or controls ( 
